Zeltia
| Company type | Sociedad Anónima |
|---|---|
| BMAD: ZEL | |
| ISIN | ES0184940817 |
| Industry | Pharmaceutical |
| Founded | Vigo, Galicia, Spain (August 3, 1939) |
| Defunct | 2015 |
| Headquarters | Madrid , Spain |
Area served | Worldwide |
Key people | José Fernández Sousa-Faro (Chairman) |
| Products | Pharmaceuticals |
| Revenue | US$176 million (2009) |
| (US$46.3) million (2009) | |
| (US$40.3) million (2009) | |
| Total assets | US$302.9 million (2009) |
| Total equity | US$59 million (2009) |
| Subsidiaries | PharmaMar, Genómica, Sylentis, Zelnova, Xylazel |
| Website | www |
| Footnotes / references | |
Zeltia is a former Spanish pharmaceutical company which operated through a variety of subsidiaries in the pharmaceutical and chemical industries. As of 2007, Zeltia's research activities in the pharmaceutical area had not resulted in a marketed product. However, the company's majority shareholder and chairman are the same person, which has relieved the pressure which many CEOs have experienced to produce immediate returns.